Table 1 Calculations of the seven scoring models to predict TACE response for intermediate-stage HCC patients
Score | Parameters included | Points | Risk | |
|---|---|---|---|---|
ALBI-TAE score | ALBI grade | 2–3 | 0 | A (Low risk) |
AFP | > 200 ng/mL | 1 | B | |
Up-to-11 | Out | 2 | C | |
3 | D (Very high risk) | |||
Bolondi’s subclassification for BCLC-B | Child–Pugh score (CPS) | CPS 5–7, Up-to-7: within, ECOG 0 | B1 (Low risk) | |
Up-to-7 | CPS 5–6, Up-to-7: beyond, ECOG 0 | B2 | ||
ECOG status | CPS 7, Up-to-7: beyond, ECOG 0 | B3 | ||
No portal vein thrombosis | CPS 8–9, Up-to-7: any, ECOG 0–1 | B4 (High risk) | ||
HAP score | Tumor size | > 7 cm | 0 | A (Low risk) |
AFP | > 400 ng/mL | 1 | B | |
Albumin | < 36 g/L | 2 | C | |
Bilirubin | > 17 µmol/L | ≥ 3 | D (High risk) | |
mHAP-II score | Tumor size | > 7 cm | 0 | A (Low risk) |
Tumor number | ≥ 2 lesions | 1 | B | |
AFP | > 400 ng/mL | 2 | C | |
Albumin | < 36 g/L | ≥ 3 | D (High risk) | |
Bilirubin | > 17 µmol/L | |||
Tumor burden score | Largest tumor diameter (cm) | Square root [(largest tumor diameter)2 + (number of tumors)2] | < 3.36 | A (Low risk) |
Number of tumors | 3.36–13.74 | B | ||
> 13.74 | C (High risk) | |||
Six-and-twelve score | Largest tumor diameter (cm) | Sum | ≤ 6 | A (Low risk) |
Tumor numbers | 7–12 | B | ||
> 12 | C (High risk) | |||
Seven-eleven criteria | Largest tumor diameter (cm) | Sum | ≤ 7 | A (Low risk) |
Tumor numbers | 7–11 | B | ||
> 11 | C (High risk) | |||